ArticleResearch square2023
Evolved bacterial siderophore-mediated antibiotic cross-protection.
Anna Clara M Galdino, Mylene Vaillancourt, Diana Celedonio, Kara Huse, Yohei Doi, Janet S Lee, Peter Jorth
Open access · greenAbstract readPreprint
In one paragraphArticle in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors at 3 institutions in 2 countries.
Anna Clara M GaldinoDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048 USA.
Mylene VaillancourtDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048 USA.
Diana CeledonioDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048 USA.
Kara HuseDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048 USA.
Yohei DoiAcute Lung Injury Center of Excellence, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine; Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Janet S LeeAcute Lung Injury Center of Excellence, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine; Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Peter JorthDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048 USA.ORCID 0000-0002-0981-740X Cedars-Sinai Medical Center · USFujita Health University · JPUniversity of Pittsburgh · US
Funding
Regulation of Cardiolin Byosynthesis in Epithelial InjuryP01HL114453 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MCVERRY, BRYAN J · 2014 to 2023
$21.3MMechanisms of host protection against pathogen-secreted proteases in acute lung injuryR01HL136143 · NHLBI · WASHINGTON UNIVERSITY · PI LEE, JANET SOJUNG · 2017 to 2024
$4.4MMechanisms of cefiderocol resistanceR21AI151362 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2020 to 2021
$420kDetermining mechanisms and prevalence of virulence-enhancing resistance mutationsK22AI127473 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI JORTH, PETER ALLAN · 2018 to 2019
$268kNHLBI NIH HHS P01 HL114453NHLBI NIH HHS R01 HL136143NIAID NIH HHS K22 AI127473NIAID NIH HHS R21 AI151362
6 · The paper itselfAbstract
Antibiotic cross-protection enables resistant bacteria to protect other bacteria that would be otherwise susceptible to the drug. Cefiderocol is the first siderophore cephalosporin antibiotic approved for treating Gram-negative bacterial infections, including carbapenem-resistant
Identifiers
PMID37292841
PMCPMC10246284
OpenAlexW4376867414
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390